Mirvaso Gel (Brimonidine 0.33%)

Mirvaso is the new FDA approved treatment from Galderma that was previously known as Sansrosa, CD07805/47 and Col-118. Mirvaso is the only topical treatment officially approved for the relief of the red face of rosacea. Mirvaso is Brimonidine Topical Gel 0.33% and is available in 30g and 45g tubes, on prescription only. It is used once per day and can last as long as 12 hours.

See below for Mirvaso User Reviews, news and updates

Recent Rosacea Blog Posts

Severe rosacea treated with Accutane, Prednisolone, Azithromycin, Mirvaso, and Metrogel

This paper from Drugs R&D, details an extensive treatment regimen undertaken to deal with a patient with a severe case of rosacea. Click the photo above for a larger view of their symptoms and how they improved over time. Note that only one side of their face was treated with Mirvaso in the hours before […]

Continue Reading

Mirvaso and Rhofade are very different indeed

Some laboratory based research has for the first time given us a highly detailed view of the method of action of 2 recently approved treatments for the redness of rosacea. The two treatments, brimonidine based Mirvaso, and oxymetazoline based Rhofade have been shown by this research to differ in their method of action. Although brimonidine […]

Continue Reading

Mirvaso plus Soolantra – better together

This just published research suggests that you can successfully treat rosacea with Mirvaso and Soolantra at the same time. So if you are suffering from the red face and pustules and papules of rosacea, this paper suggests that using Mirvaso and Soolantra together is a viable option. Previously Mirvaso and Soolantra have been shown to […]

Continue Reading

Galderma CareConnect Savings Card

A little known program from Galderma may offer access to expensive rosacea treatments for many currently unaware rosacea sufferers. Galderma CareConnect offers rebates, for insured and fully uninsured rosacea sufferers for prescription treatments well known to rosacea sufferers; – Oracea, Mirvaso, Soolantra and Metrogel. The program is being promoted as being offered by `any US […]

Continue Reading

Mirvaso rebound after 2 years of happiness

A paper in the Journal of Drugs in Dermatology is detailing a case report where rebound associated with Mirvaso occured after 2 years of otherwise successful use. The patient was enjoying the benefits of Mirvaso – a blanching of their erythema, for 2 years when they unexpectedly experienced rebound redness. The patient noted that Mirvaso […]

Continue Reading

 

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.